Immediately after switching the page, it will work with CSR.
Please reload your browser to see how it works.

Source:https://github.com/SoraKumo001/next-streaming

⬅️ Cost of developing new drugs may be lower than industry claims: trial
tompccs 12 daysReload
You can't compare running a clinical trial for a drug targeting a communicable disease in the developing world to trials for treatments of complex diseases in rich countries where you need serology, histopathology and radiological endpoints.

Worth noting as well that J&J have shut down their entire division in communicable diseases because it was so unprofitable for them.

(Source: I work in this industry)

kazinator 12 daysReload
The cost of developing drugs is high because of all the drugs that fail, after requiring lots of money to develop. You can't just look at the successful drug and say that's the cost. There are drugs that don't get to the trial stage, so also you can't just look at trials, even if you include failed ones.

The researchers cited in this article seem to be promulgating the fallacy that we need only look at the cost of a successful drug trial, and that's the cost. The drugs magically appeared out of nowhere, for free, and equally magically, they are working drugs, so we already know our trial will succeed. It's just a charade we have to go pay for to get the government's rubber stamp, and then it's all good!

ano-ther 12 daysReload
I'd be eager to learn more, but it seems that they have only published the topline figures [1] and some of their methodology [2]. Details will follow in a journal.

Perhaps worth noting that development cost account for more than the phase 2-3 studies and that cost are lower for combinations of known drugs. But yes, 34 million is a lot less than 3 billion.

[1] https://msfaccess.org/precedent-setting-move-towards-drug-de...

> *Total costs were €33.9 million. While the topline results were presented at the WHO PPRI conference, the full detailed costs of the clinical trial have been submitted for a peer-review publication to a journal. In the full publication, the costs are broken down into 27 cost categories, by year, and by trial site, in order to offer a high level of transparency.

[2] https://msfaccess.org/transparency-core-clinical-trial-cost-...

lr4444lr 12 daysReload
I'm not clear from the article whether this also accounts for recouping the cost of _failed_ drugs.
streptomycin 12 daysReload
Its own bill for landmark trials of a four-drug combination treatment for drug-resistant tuberculosis came to €34m (£29m).

Okay, how does that compare to what pharma companies spend? The article cites some unrelated numbers, doesn't actually compare.

A quick Google search says:

The average cost of phase 1, 2, and 3 clinical trials across therapeutic areas is around $4, 13, and 20 million respectively.

So... not really that different? What's the big deal here?